EnteroMedics Company Profile (NASDAQ:ETRM)

Analyst Ratings

Consensus Ratings for EnteroMedics (NASDAQ:ETRM) (?)
Ratings Breakdown: 1 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $9.00 (3,830.13% upside)

Analysts' Ratings History for EnteroMedics (NASDAQ:ETRM)
Show:
DateFirmActionRatingPrice TargetActions
6/9/2016Roth CapitalDowngradeBuy -> Neutral$3.00 -> $3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/10/2015Canaccord GenuityLower Price Target$37.50 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/20/2015Craig HallumLower Price TargetBuy$75.00 -> $30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/28/2014 forward)

Earnings

Earnings History for EnteroMedics (NASDAQ:ETRM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/5/2016Q1($0.80)($0.94)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/17/2016Q315($0.90)($0.95)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.10)($0.10)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/18/2015Q414($0.10)($0.09)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2014Q3 14($0.10)($0.08)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q2($0.10)($0.11)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2014Q1 14($0.10)($0.10)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/12/2014Q413($0.10)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/31/2013Q313($0.11)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2013Q2 2013($0.13)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2013Q1 2013($0.13)($0.14)$0.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/13/2013Q4 2012($0.14)($0.17)$0.36 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for EnteroMedics (NASDAQ:ETRM)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.80)($0.05)($0.43)
Q2 20161($0.69)($0.69)($0.69)
Q3 20161($0.53)($0.53)($0.53)
Q4 20161($0.41)($0.41)($0.41)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for EnteroMedics (NASDAQ:ETRM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for EnteroMedics (NASDAQ:ETRM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/3/2016Peter M DelangeSVPBuy20,000$0.55$11,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2015Mark B KnudsonCEOBuy303,000$0.25$75,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2014Cathy FriedmanDirectorBuy11,800$1.70$20,060.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/8/2014Luke EvninDirectorSell556,585$2.50$1,391,462.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/27/2013Anthony P JanszDirectorBuy150,000$0.95$142,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for EnteroMedics (NASDAQ:ETRM)
DateHeadline
07/28/16 02:38 PMTwo Stocks within Analysts Limelight: EnteroMedics Inc. (NASDAQ:ETRM) , Regulus Therapeutics Inc. (NASDAQ:RGLS) - Street Updates
07/28/16 02:38 PMStocks Showing Trends: EnteroMedics Inc. (NASDAQ:ETRM), LendingClub Corporation (NYSE:LC) - News Oracle
07/28/16 06:47 AMCan Shares Of EnteroMedics Inc. (NASDAQ:ETRM) Hit $7? - Investor Newswire
07/27/16 06:52 AMOverview of Analysts Suggestions: Merck & Company, Inc. (NYSE:MRK) , EnteroMedics Inc. (NASDAQ:ETRM) - Street Updates
07/26/16 03:55 PMEye Catching Stock: EnteroMedics Inc. (NASDAQ:ETRM) - News Oracle
07/26/16 06:01 AMAnalyst's Stocks Rating Activity: ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) , EnteroMedics Inc. (NASDAQ:ETRM) - Street Updates
07/25/16 03:57 PMHC Stocks Watchful: Amgen, Inc. (NASDAQ:AMGN) EnteroMedics Inc (NASDAQ:ETRM) - share market updates (press release)
07/25/16 03:57 PMCurrent EnteroMedics Inc. (NASDAQ:ETRM) PT Means Stock Is Worth Almost $7 - Review Fortune
07/25/16 08:35 AMCan EnteroMedics Inc. (NASDAQ:ETRM) Keep Up with Analyst Expectations? - Investor Newswire
07/25/16 08:35 AMAnalysts Watching Stocks: Gilead Sciences, Inc. (NASDAQ:GILD) , EnteroMedics Inc. (NASDAQ:ETRM) - Street Updates
07/23/16 07:59 AMEquity Roundup: Stock Performance Focus on EnteroMedics Inc. (NASDAQ:ETRM) - Press Telegraph
07/23/16 07:59 AMShares Stumbling of Late: EnteroMedics Inc. (NASDAQ:ETRM) - TGP
07/22/16 03:50 PMStock's Trend Analysis Report: EnteroMedics Inc. (ETRM), Merrimack Pharmaceuticals, Inc. (MACK), CIT Group Inc. (CIT) - iStreetWire
07/22/16 03:50 PMStock Update: Tracking Unusual Volume for EnteroMedics Inc. (NASDAQ:ETRM) - Engelwood Daily
07/20/16 05:09 PMEnteroMedics Inc. (NASDAQ:ETRM): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/20/16 05:09 PMWill EnteroMedics Inc. (NASDAQ:ETRM) Surprise Analysts? - Investor Newswire
07/20/16 05:09 PMIs $7 Price Target Attainable For EnteroMedics Inc. (NASDAQ:ETRM)? - Investor Newswire
07/20/16 05:47 AMAnalysts Watching Stocks Update: Pfizer, Inc. (NYSE:PFE) , EnteroMedics Inc. (NASDAQ:ETRM) - Street Updates
07/18/16 04:03 PMAnalysts Reviewing Stocks: EnteroMedics Inc. (NASDAQ:ETRM) , Mylan N.V. (NASDAQ:MYL) - Street Updates
07/18/16 04:03 PMSirius XM Holdings Inc. (NASDAQ:SIRI) & EnteroMedics Inc (NASDAQ:ETRM) News Review - Money News (press release)
07/18/16 09:04 AMEnteroMedics Inc. (NASDAQ:ETRM) Wall Street Analyst Recommendation Outlook - TGP
07/18/16 09:04 AMStock Analysis review: EnteroMedics Inc. (NASDAQ:ETRM) - News Oracle
07/17/16 03:36 PMEnteroMedics Inc. (ETRM) Broker Price Targets For The Coming Week - Fiscal Standard
07/16/16 07:20 AMNoting Unusual Volume on Shares of EnteroMedics Inc. (NASDAQ:ETRM) - Engelwood Daily
07/15/16 05:58 AMNotable Moving Stocks: EnteroMedics Inc. (NASDAQ:ETRM) , ZIOPHARM Oncology Inc (NASDAQ:ZIOP) - Street Updates
07/15/16 05:58 AMAnalysts Observing Stocks: EnteroMedics Inc. (NASDAQ:ETRM) , Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) - Street Updates
07/15/16 05:58 AMAre These The Right Priorities For EnteroMedics Inc. (NASDAQ: ETRM)? - Scibility Media
07/15/16 05:04 AMENTEROMEDICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits -
07/14/16 07:07 AMStock Watch: Unusual Volume Seen on Shares of EnteroMedics Inc. (NASDAQ:ETRM) - Engelwood Daily
07/14/16 07:07 AMStrong Sell Calls For EnteroMedics Inc. (NASDAQ:ETRM) At 0 - Investor Newswire
07/11/16 03:53 PMWall Street Ratings and Target Price Views on EnteroMedics Inc. (NASDAQ:ETRM) - Telanagana Press
07/08/16 03:54 PMActive Stocks: EnteroMedics Inc. (NASDAQ:ETRM), SM Energy Company (NYSE:SM), Ladder Capital Corp (NYSE ... - KC Register
07/08/16 03:54 PMAnalysts watching two Stocks: Bristol-Myers Squibb Company (NYSE:BMY) , EnteroMedics Inc. (NASDAQ:ETRM) - Street Updates
07/07/16 05:47 AMCan EnteroMedics Inc. (NASDAQ:ETRM) Improve on the Earnings Front? - Engelwood Daily
07/07/16 05:47 AMEnteroMedics Inc. (NASDAQ:ETRM) Expected to Reach Highs Of $7 - Investor Newswire
07/07/16 05:47 AMEnteroMedics Inc. (ETRM) Current Analyst Ratings - Fiscal Standard
07/06/16 08:39 AMNew Broker Ratings For EnteroMedics Inc. (ETRM) - FTSE News
07/04/16 03:36 PMCompany Stock Lower on the Week EnteroMedics Inc. (NASDAQ:ETRM) - Engelwood Daily
06/29/16 06:00 AMEnteroMedics Highlights Recent Patient Success with vBloc® Therapy in Combination with vBloc® Achieve Program - [PR Newswire] - ST. PAUL, Minn., June 29, 2016 /PRNewswire/ -- EnteroMedics Inc. (ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced a recent successful outcome following implantation of vBloc® Neurometabolic Therapy. The surgery was performed by Charles Procter, MD, Bariatric and General Surgeon at the Beltline Bariatric and Surgical Group in Atlanta, Georgia, where five vBloc procedures have been performed to date. After three months of treatment with vBloc Therapy and participation in vBloc® Achieve, the Company's comprehensive weight loss support program, the patient has lost approximately 25 pounds, and has had his Body Mass Index (BMI) reduced from 37.5 kg/m2 to 34 kg/m2.
06/28/16 08:47 AMCovering the Bases on EnteroMedics Inc. (NASDAQ:ETRM): Where is the Stock Going? - Press Telegraph
06/28/16 05:04 AMENTEROMEDICS INC Files SEC form 8-K, Other Events -
06/22/16 09:04 PMCan EnteroMedics Inc. (NASDAQ:ETRM) Meet Analysts Expectations? - Stocks Daily
06/22/16 09:04 PMStrong Buy Calls Count For EnteroMedics Inc. (NASDAQ:ETRM) At 1 - Investor Newswire
06/20/16 10:07 AMRoth Capital reported on (NASDAQ:ETRM) EnteroMedics Inc, cutting its stock price target to $1 earlier today
06/16/16 09:08 PMTrend Of Rating Given To EnteroMedics Inc. (NASDAQ:ETRM) - Investor Newswire
06/16/16 09:08 PMBrokers Issue Average Price Target Of 2.77 On EnteroMedics Inc. (ETRM) - Fiscal Standard
06/11/16 06:55 AMNASDAQ New Lows: Forbes Energy Services Ltd. (NASDAQ:FES), EnteroMedics Inc. (NASDAQ:ETRM), WL Ross ... - KC Register
06/10/16 07:01 AMEnteroMedics Cut By Roth Capital On Utilization Growth
06/09/16 03:57 PMEnteroMedics Cut By Roth Capital On Utilization Growth - Benzinga
06/09/16 07:52 AMEnteroMedics downgraded by ROTH Capital -

Social

About EnteroMedics

EnteroMedics logoEnteroMedics Inc. (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company's neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve using high frequency, low energy, electrical impulses. The Company's initial product is the Maestro System, which uses VBLOC therapy to affect metabolic regulatory control, limits the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company has approvals to commercially launch its product, the Maestro Rechargeable System, in the United States, Australia, the European Economic Area and other countries.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: Health Care Equipment
  • Exchange: NASDAQ
  • Symbol: ETRM
  • CUSIP: 29365M20
Key Metrics:
  • Previous Close: $0.23
  • 50 Day Moving Average: $0.314
  • 200 Day Moving Average: $0.782
  • P/E Ratio: N/A
  • P/E Growth: -0.290
  • Market Cap: $2.12M
  • Beta: 2.09
  • Current Year EPS Consensus Estimate: $-2.860 EPS
  • Next Year EPS Consensus Estimate: $-1.200 EPS
Additional Links:
EnteroMedics (NASDAQ:ETRM) Chart for Thursday, July, 28, 2016